ARYx to Present at the Jefferies 3rd Annual Healthcare Conference

FREMONT, Calif.--(Business Wire)--
ARYx Therapeutics, Inc. (NASDAQ:ARYX) today announced that it will present at
the Jefferies & Company 3rd Annual Healthcare Conference on Wednesday, June 17,
2009 at 2:45 p.m. Eastern Time. A live webcast of the presentation may be
accessed at the ARYx website http://www.aryx.com. The presentation will be
archived for 30 days.

About ARYx Therapeutics, Inc.

ARYx Therapeutics is a biopharmaceutical company focused on developing a
portfolio of internally discovered products designed to eliminate known safety
issues associated with well-established, commercially successful drugs. ARYx
uses its RetroMetabolic Drug Design technology to design structurally unique
molecules that retain the efficacy of these original drugs but are metabolized
through a potentially safer pathway to avoid specific adverse side effects
associated with these compounds. ARYx currently has four products in clinical
development: an oral anticoagulant agent for patients at risk for the formation
of dangerous blood clots, tecarfarin (previously ATI-5923); an oral
anti-arrhythmic agent for the treatment of atrial fibrillation, budiodarone
(previously ATI-2042); a prokinetic agent for the treatment of various
gastrointestinal disorders, ATI-7505; and, an agent for the treatment of
schizophrenia and other psychiatric disorders, ATI-9242. Please visit our web
site at www.aryx.com for additional information.

ARYx Therapeutics, Inc.
David Nagler, 510-585-2200 ext. 211
Vice President Corporate Affairs

Copyright Business Wire 2009